There are currently no items in this Watchlist. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. This may be the next lithium giant to feed surging global battery demand for EVs! Galapagos NV is a Belgium-based clinical-stage biotechnology company. Based on aggregate information from My MarketBeat watchlists, some companies that other Galapagos investors own include Gilead Sciences (GILD), Celyad Oncology (CYAD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), argenx (ARGX), AbbVie (ABBV), Biogen (BIIB), Pharming Group (PHGUF), The Trade Desk (TTD) and Collegium Pharmaceutical (COLL). 6 employees have rated Galapagos CEO Onno van de Stolpe on Glassdoor.com. Galapagos has a P/B Ratio of 1.25. Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. One share of GLPG stock can currently be purchased for approximately $73.14. Galapagosâ core research areas are inflammatory, fibrotic, and kidney diseases, where our clinical activity is focused across several indications. View our full suite of financial calendars and market data tables, all for free. Earnings for Galapagos are expected to decrease in the coming year, from ($6.00) to ($6.19) per share. Galapagos total number of employees in 2019 was 1,003, a 38.34% increase from 2018. MarketBeat's community ratings are surveys of what our community members think about Galapagos and other stocks. Gilead paid Shares of GLPG can be purchased through any online brokerage account. ... Galapagos stock ⦠Receive a free world-class investing education from MarketBeat. This decrease in share price is likely because Galápagos has no initiatives specifically dedicated to COVID-19, so it is not at the forefront of many investorsâ minds. 18 equities research analysts have issued 12-month target prices for Galapagos' stock. In a report released today, Derek Archila from Stifel Nicolaus reiterated a Hold rating on Galapagos (GLPG â Research Report).The companyâs shares closed last Wednesday at $82.32, close to its 52-week low of $81.37. Learn more about MarketBeat. In a report issued on October 13, Barclays also maintained a Hold rating on the stock with a EUR125.00 price target. Galapagos will ⦠The biotechnology company can be reached via phone at 321-534-2900 or via email at [email protected]. Galapagos Receives Rating Downgrade, Stock Skids. Pharmaceutical research companyâs on the other hand have seen a modest rise and are expected to outperform the market in 2021 as investors look beyond tech stocks. * Jazz Pharmaceuticals plc to acquire GW Pharmaceuticals Plc â WSJ (2/3/21)Download List (or) Export the above Table: The Complete List of Foreign Biotech Stocks Trading on the NASDAQ (in Excel); Biotech ETFs: View analysts' price targets for Galapagos or view top-rated stocks among Wall Street analysts. To see all exchange delays and terms of use please see disclaimer. Stock analysis for Galapagos NV (GLPG:EN Amsterdam) including stock price, stock chart, company news, key statistics, fundamentals and company profile. MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Here’s what to expect, Analysts Offer Insights on Healthcare Companies: Galapagos (GLPG) and InflaRx (IFRX), Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday, Galapagos NV (GLPG) Q1 2021 Earnings Call Transcript, Galapagos (GLPG) Gets a Buy Rating from Raymond James, Top Analyst Upgrades and Downgrades: Alphabet, Facebook, Harley-Davidson, JetBlue, Lowe’s, Occidental, Overstock.com, Snap, Southwest Air and More, Drugmakers Are Vying for a Multibillion-Dollar Market, A Short Delay Is Still Bad News for AbbVie, Maxim Group Maintains Their Hold Rating on Galapagos (GLPG), Galapagos (GLPG) Receives a Hold from Stifel Nicolaus, Analysts Offer Insights on Healthcare Companies: Galapagos (GLPG), ADMA Biologics (ADMA) and Cardiff Oncology (CRDF), Sands Capital Trims Microsoft, Exits Regeneron Pharmaceuticals, Top Analyst Upgrades and Downgrades: Advance Auto, Dish Network, Intuit, Kroger, Palo Alto, Starbucks, Texas Instruments and More, Galapagos: Upside Optionality Remains Despite Clinical Trial Failure, Analysts Offer Insights on Healthcare Companies: Galapagos (GLPG) and Homology Medicines (FIXX), Gilead (GILD) & Galapagos Discontinue Development of IPF Drug, Raymond James Remains a Hold on Galapagos (GLPG), Gilead (GILD) Tops Q4 Earnings & Sales on Strong Veklury Demand. Create a list of the investments you want to track. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. The company can thank its strategic partner Gilead (NASDAQ:GILD)for that; last August, the two companies entered into a 10-year global research and development collaboration for multiple products. Vertex Pharmaceuticalâs dominance in the cystic fibrosis space and the potential for its CF treatment in international markets make it an attractive stock. A plant-based COVID-19 vaccine from a GlaxoSmithKline alliance with Medicago shows strong antibody response, This signal is telling investors that highflying stocks are ready to fall back to Earth, says fund manager, Squarespace stock now indicated to open $45.50-$46.50, or 9%-7% below reference price, With drinkers back, 2 of Britain’s biggest pub groups are hoping for a strong rebound, Century Communities initiates quarterly dividend of 15 cents a share, European Central Bank warns on heightened risks to financial stability, Galapagos upgraded to outperform from market perform at Raymond James, Galapagos downgraded to hold from buy at Maxim Group, Galapagos stock price target cut to $138 from $155 at Stifel Nicolaus, Galapagos stock price target cut to $155 from $187 at Stifel Nicolaus, Galapagos' stock plunges 29% premarket, as partner Gilead's arthritis drug won't be approved in current form, Galapagos stock price target cut to $193 from $298 at Stifel Nicolaus, Galapagos downgraded to hold from buy at Stifel Nicolaus, Galapagos downgraded to underperform from neutral at BofA Securities, Galapagos stock price target raised to $298 from $188 at Stifel Nicolaus, Galapagos downgraded to neutral from overweight at J.P. Morgan, Galapagos downgraded to market perform at Bernstein, Galapagos stock price target raised to $209 from $140 at Instinet, Galapagos stock price target raised to $200 from $150 at SVB Leerink, Gilead, Galapagos drug fails in Phase 3 clinical study, Focus Shifts to Europe as Gilead Backs Away From Arthritis-Drug Partnership, Gilead reaches $21 billion deal for Immunomedics, Gilead arthritis drug won't be approved by FDA in current form, partner Galapagos says, Galapagos shares rise on Phase 3 studies of arthritis drug it's making with Gilead, Europe stocks sag on China trade and Hong Kong violence concerns, Gilead and Amgen will report second-quarter earnings after the closing bell. Stable Share Price: GLPG is more volatile than 90% of Dutch stocks over the past 3 months, typically moving +/- 7% a week. The company, focused in the biotechnology space, is currently trading at $183.40 after a move up of 5.40% so far today. Get daily stock ideas top-performing Wall Street analysts. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Get short term trading ideas from the MarketBeat Idea Engine. Competitors Galapagos (NASDAQ:GLPG) Vs. HZNP, CTLT, CVAC, ALNY, BMRN, and ELAN. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium. But investors in this company could end up really happy if the Lithium Megatrend continues.document.write('
'); Galapagos has received a consensus rating of Hold. 326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257 Galapagos total number of employees in 2020 was 1,304, a 30.01% increase from 2019. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Galapagos employs 1,489 workers across the globe. The stock has a consensus analyst rating of "Hold." Please log in to your account or sign up in order to add this asset to your watchlist. Pharma firm Gilead to raise Galapagos stake in $5.1 billion deal. There are currently 2 sell ratings, 10 hold ratings and 6 buy ratings for the stock. Compare Top Brokerages Here. Wall Street analysts have given Galapagos a "Hold" rating, but there may be better buying opportunities in the stock market. Cookie Notice (). Galapagos NV American Depositary Shares (GLPG) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets. Its pipeline comprises Phase 3, 2, 1, pre-c linical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The new super strain of hemp has 3X more CBD per bud than competitorsâ. Co-Founder, Chairman of the Management Board, MD & CEO, MBA, Pres, COO & Member of Management Board, Chief Bus. (Add your “outperform” vote. ), Galapagos has received 414 “underperform” votes. Galapagos boasts a huge war chest, in excess of 1.86 billion euros, to fund its research and development. Thatâs good news for people who can move now to become one of the companyâs earliest investors. The company issued 3,800,000 shares at a price of $42.43 per share. Their forecasts range from $94.00 to $290.00. Log in to see them here or sign up to get started. GLPG stock was purchased by a variety of institutional investors in the last quarter, including Capital International Investors, Orbimed Advisors LLC, Goldman Sachs Group Inc., Point72 Asset Management L.P., Millennium Management LLC, Canada Pension Plan Investment Board, Prosight Management LP, and Schonfeld Strategic Advisors LLC. Volatility Over Time : GLPG's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Dutch stocks. Galapagos NV is a European pharmaceutical research company Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. This browser is no longer supported at MarketWatch. Share your opinion and gain insight from other stock traders and investors. Galapagos has a market capitalization of $4.79 billion and generates $1.00 billion in revenue each year. Copyright © 2021 MarketWatch, Inc. All rights reserved. Since then, GLPG stock has decreased by 60.7% and is now trading at $73.14. U.S. antiviral drugmaker Gilead Sciences will invest $5.1 billion in a major expansion of its partnership with Belgo-Dutch biotech Galapagos NV , news that lifted Galapagos⦠Intraday Data provided by FACTSET and subject to terms of use. All rights reserved. View which stocks have been most impacted by COVID-19. Galapagos' management team includes the following people: This Little-Known Lithium Explorer May About to Rocket. The P/E ratio of Galapagos is -11.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. 18 brokerages have issued 12 month price targets for Galapagos' stock. View our earnings forecast for Galapagos. GLPG stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Citigroup Inc., Renaissance Technologies LLC, Envestnet Asset Management Inc., DAFNA Capital Management LLC, Northern Trust Corp, Assetmark Inc., and UBS Group AG. View the latest ratings for GLPG. Subscriber Agreement & Terms of Use,
A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GLPG, but not buy more shares or sell existing shares. Galapagos has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Galapagos' stock was trading at $186.06 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. For the best MarketWatch.com experience, please update to a modern browser. Galapagos NV NASDAQ:GLPG) shares fell 18% to $89.90 on news their Phase 3 ISABELA trial with Gilead Sciences (NASDAQ:GILD) of ziritaxestat in patients with idiopathic pulmonary fibrosis has been discontinued due to insufficient efficacy shown following a review by the Independent Data Monitoring Committee (IDMC).. Bio-Path Holdings, Inc., (NASDAQ:BPTH) shares closed up 126% to ⦠According to analysts' consensus price target of $143.82, Galapagos has a forecasted upside of 96.4% from its current price of $73.22. According to TipRanks.com, Archila is a 4-star analyst with an average return of 10.5% and a 48.5% success rate. Galapagos annual/quarterly revenue history and growth rate from 2013 to 2020. Image source: Getty Images. In the past three months, Galapagos insiders have not sold or bought any company stock. On average, they expect Galapagos' share price to reach $143.82 in the next twelve months. Whether youâre looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. The pharma company stock was recently downgraded by JPMorgan Chase & Co. which pulled its rating from Overweight to Neutral. View all of GLPG's competitors. Sign-up to receive the latest news and ratings for Galapagos and its competitors with MarketBeat's FREE daily newsletter. This puts Onno van de Stolpe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. It operates through the Research & Development and Fee-for-Services segment. A good way to spot top clinical-stage and early-entry biotech stocks is finding those firms with top-notch partners. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Visit a quote page and your recently viewed tickers will be displayed here. See what's happening in the market right now with MarketBeat's real-time news feed. Want to see which stocks are moving? MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Galapagos NV American Depositary Shares (GLPG) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. MarketBeat thinks these five companies may be even better buys.View MarketBeat's top stock picks here. Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Galapagos, including Horizon Therapeutics Public (HZNP), Catalent (CTLT), CureVac (CVAC), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical ⦠Export data to Excel for your own analysis. Galapagos is a pharmaceutical research company based in Belgium. Galapagos trades on the NASDAQ under the ticker symbol "GLPG.". Pharmaceutical research companyâs will be in general a good investment in 2021. Galapagos NV (GLPG) is making a move up in the market today. Top institutional investors include Capital International Investors (2.80%), Point72 Asset Management L.P. (0.71%), Goldman Sachs Group Inc. (0.40%), Orbimed Advisors LLC (0.35%), Millennium Management LLC (0.31%) and Morgan Stanley (0.25%). Historical and current end-of-day data provided by FACTSET. The biotechnology company earns $167.83 million in net income (profit) each year or $5.46 on an earnings per share basis. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Only 11.17% of the stock of Galapagos is held by institutions. MarketBeat just released five new stock ideas, but Galapagos wasn't one of them. On average, they expect Galapagos' stock price to reach $143.82 in the next twelve months. Galapagos has received 446 “outperform” votes. The latest Galapagos NV Ordinary Shares NPV (CDI) share price. So what Privacy Notice, and
Only 2.91% of the stock of Galapagos is held by insiders. Morgan Stanley, Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers. Galapagos is a commercial-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel modes of action. The official website for Galapagos is www.glpg.com. Stock analysis for Galapagos NV (GLPG:EN Brussels) including stock price, stock chart, company news, key statistics, fundamentals and company profile. (Add your “underperform” vote.). Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. The company has sites in several locations across Europe. In terms of biotech companies, there are several factors that have the ability to lead to price movement in the market. Interactive chart of Galapagos (GLPG) annual worldwide employee count from 2013 to 2020. View which stocks are hot on social media with MarketBeat's trending stocks report. Galapagos NV (formerly known as Galapagos Genomics) is a European pharmaceutical research company which was founded in 1999. Galapagos does not have a long track record of dividend growth. They are not Tesla investors. Galapagos' stock is owned by many different retail and institutional investors. Its breakthrough super strain of hemp could lead an Oregon agribusiness to blow up the North American cannabis market. Will Strong Veklury Sales Aid Gilead's (GILD) Q4 Earnings. This suggests a possible upside of 96.6% from the stock's current price. Galapagos total number of employees in 2018 was 725, a 20.83% increase from 2017. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLPG, but not buy additional shares or sell existing shares. Our Accessibility Statement | Terms of Service | Do Not Sell My Information. Our ambition is to become a leading global biopharmaceutical company, focused on the discovery, development and commercialization of innovative medicines that will improve people's lives. The consensus among Wall Street research analysts is that investors should "hold" Galapagos stock. Galapagos stock price target cut to $155 from $187 at Stifel Nicolaus Aug. 19, 2020 at 6:58 a.m. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Galapagos is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. That allowed Galapagos to exit September with nearly $6.2 billion in cash and no doubt helped to fuel the pharma stock's rise. Galapagos currently has 2 sell ratings, 10 hold ratings and 6 buy ratings from Wall Street analysts. Learn about financial terms, types of investments, trading strategies and more. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. Vote “Underperform” if you believe GLPG will underperform the S&P 500 over the long term. Something went wrong while loading Watchlist. Their forecasts range from $94.00 to $290.00. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. The company's average rating score is 2.22, and is based on 6 buy ratings, 10 hold ratings, and 2 sell ratings. The Stock: At its peak this past February, Galápagos was trading at $ 274.03, whereas now the share price has decreased by about 27% to approximately $200. Fundamental company data provided by Zacks Investment Research. Intraday data delayed at least 15 minutes or per exchange requirements. Archila covers the Healthcare sector, focusing on stocks ⦠Galapagos' mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. And Galapagos NV (NASDAQ: GLPG) couldnât have picked a ⦠#2 Galapagos ⦠You can opt out at any time. This suggests a possible upside of 94.6% from the stock⦠Looking for new stock ideas? Vote “Outperform” if you believe GLPG will outperform the S&P 500 over the long term. Identify stocks that meet your criteria using seven unique stock screeners. The Oregon grower has cracked the cannabis yield code. See todayâs analyst top recommended stocks >> Apellis Pharmaceuticals (APLS) Onno van de Stolpe has an approval rating of 100% among Galapagos' employees. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb.The CEO is the Dutchman Onno van de Stolpe.. Filgotinib. (GLPG) raised $161 million in an IPO on Thursday, May 14th 2015. By using this site you agree to the
You may vote once every thirty days. Should you be buying GLPG stock or one of its competitors? Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Find the latest Galapagos NV (GLPG) stock discussion in Yahoo Finance's forum. Galapagos has received 51.86% “outperform” votes from our community. The company develops drugs against rheumatoid arthritis, crohn's disease, ⦠Galapagos does not currently pay a dividend. Moreover, even after outperforming Galapagos significantly year-to-date, Vertex stock still offers additional upside potential for investors over the coming year. Galapagos has an analyst consensus of Hold, with a price target consensus of $141.96, which is a 10.0% upside from current levels. Find the latest Galapagos NV (GLPG) stock quote, history, news and other vital information to help you with your stock trading and investing. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Gilead stock fell less than 1% to 58.94.. GLPG Stock Tumbles On Reformatted Deal. View analyst ratings for Galapagos or view top-rated stocks. On today's stock market, GLPG stock toppled 18.8% to 97.02. Some companies that are related to Galapagos include UCB (UCBJF), Catalent (CTLT), Elanco Animal Health (ELAN), Alnylam Pharmaceuticals (ALNY), Zai Lab (ZLAB), BioMarin Pharmaceutical (BMRN), Grifols (GRFS), Ono Pharmaceutical (OPHLF), Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Maravai LifeSciences (MRVI), United Therapeutics (UTHR) and BridgeBio Pharma (BBIO). Galapagos is headquartered at GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. ⦠Have Watchlists? 18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Galapagos in the last twelve months. Officer & Member of Management Board, Chief Scientific Officer & Member of Management Board, Chief Medical Officer & Member of Management Board, Chief Commercial Officer & Member of Management Board, Global Head Communications & Public Affairs, Start Your Risk-Free Trial Subscription Here, The Container Store Has What Every Growth Stocks NeedsÂ, Donât Rush To Buy Walmart, Extra Low Prices Are On The WayÂ, Legal Issues Behind It, IBIO Stock May Be a Long Play For Risk-Tolerant Investors, Steel Producers Extend Their One-Year Gains On Strong Demand, Lumentum Stock Providing Opportunistic Pullbacks, 3 Stocks to Play the Shopping Mall Revival, Snowflake (NYSE: SNOW) Starts To Look Hot, 7 Cyclical Stocks That Can Help You Play Defense, 7 Stocks That Could Benefit From a Capital Gains Tax Hike, 7 Forever Stocks That Are Never Bad to Buy, 7 Stocks That Still Have Upside For Investors to Buy, 7 Precious Metals Stocks That Will Keep Your Portfolio On Trend, 7 Bellwether Stocks Signaling a Return to Normal, 7 Electric Vehicle (EV) Stocks That Are Ready to Rebound, 7 Sports Betting Stocks That Will Shine Beyond March Madness, 7 Stocks That Cathie Wood is Buying And You Should Too, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, Darwin Island in the Galapagos is an amazing place usa today 0 months ago - USA TODAY, Galapagos announces first patient enrolled in FILOSOPHY study to advance understanding of Jyseleca (filgotinib) effectiveness and safety in a real-world setting - Yahoo Finance, Galapagos announces first patient enrolled in FILOSOPHY study to advance understanding of Jyseleca - GlobeNewswire, Famed Darwinâs Arch in Galapagos Islands collapses due to erosion, officials say - USA TODAY, Galapagos announces first patient enrolled in FILOSOPHY study to advance understanding of Jyseleca (filgotinib) effectiveness and safety in a real-world setting, Galapagos (NASDAQ:GLPG) Shares Gap Down to $77.00, Galapagos (NASDAQ:GLPG) Price Target Increased to $118.00 by Analysts at Morgan Stanley, Form 6-K GALAPAGOS NV For: May 11 - StreetInsider.com, JPMorgan Chase & Co. Reaffirms "Neutral" Rating for Galapagos (NASDAQ:GLPG), Galapagos (NASDAQ:GLPG) Shares Gap Down to $75.04, view top-rated stocks among Wall Street analysts, Receive Analysts' Upgrades and Downgrades Daily.
© American Consumer News, LLC dba MarketBeat® 2010-2021. ... All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but ⦠Cannabis Super Strain Could Destroy Competitors. All quotes are in local exchange time.
Mecklenburg County Health Department Covid Vaccine Appointment,
What Is The Point Of Cryptocurrency,
Leonovus Aktie Forum,
Vascular Access Education Program,
Crawley Town Wages 2021,
Terjadi Kesalahan Saat Memutar Video Di Hp Xiaomi,
